SynaptixBio

Rare diseases
#FDA #Golden Triangle #Investment #Priority Review #Rare disease #SynaptixBio #UK pharma

Rare disease biotech investment grows but UK lags

Investment in rare disease biotechs has increased following renewal of the FDA’s Priority Review Voucher (PRV) programme, according to SynaptixBio, but the United States remains dominant compared to the UK. In February 2026, the PRV programme was signed into law and will remain in place until reviewed again in September… Read More

#News

FDA headquarters
#Clinical trials #MHRA #Rare disease #Regulatory #SynaptixBio

UK should offer US-style incentives in rare diseases, says biotech

The UK Medicines & Healthcare Regulatory Agency (MHRA) is consulting on a new regulatory framework for bringing rare disease drugs more quickly to market.  The new Rare Disease Therapies Regulatory Framework is intended to “support earlier, more frequent, and iterative engagement with developers, providing structured regulatory flexibility… Read More

#News #Regulatory

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

DDW Highlights: 21 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, key breakthroughs emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical… Read More

#Podcasts

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

This week in Drug Discovery (13 – 17 April) 

News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW.  This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK.  The top stories:    Novel therapy could slow tumour growth… Read More

#News

CANTAB
#Clinical research #SynaptixBio

Speech overlooked as clinical marker, biotech says 

Speech is an ‘underestimated’ clinical marker in neurodegenerative disease research, SynaptixBio has said.  The biotech, which became the only company to commercialise a treatment for the rare disease H-ABC, is set to launch a study into speech as a non-invasive, digital clinical marker in neurodegenerative disease research.  … Read More

#News

#FDA #Priority Review #Rare diseases #SynaptixBio

US Senate reauthorises Priority Review Voucher scheme 

The US Senate has reauthorised the US Food and Drug Administration (FDA)’s Priority Review Voucher (PRV), helping biotech companies to develop rare disease drugs.  The PRV programme, which incentivises rare disease drug development, was reauthorised on 30 January, with President Donald Trump signing the bill. … Read More

#News #Regulatory

Demyelination of neuron
#FDA #Priority Review #SynaptixBio

Rare disease drug development scheme welcomed by biotech sector 

The renewal of the US priority review voucher (PRV) is vital for the biotech sector, SynaptixBio CEO Dan Williams has said.  The US Food and Drug Administration (FDA)’s PRV scheme, designed to incentivise rare disease drug development, was reauthorised by the US House of Representatives on December 1.  … Read More

#News #Regulatory

DNA sequencing
#Genetic diseases #Genetics / genomes #Rare diseases #SynaptixBio #UK #UK government

UK genetic screening plan welcomed by biotech

The UK Government has announced that every newborn baby in England will have their genetic code mapped to test for a wide range of conditions, part of a plan that will also see £650m invested in DNA research by 2030.  The Department for Health and Social Care… Read More

#News

Demyelination of neuron
#Antisense Oligonucleotides (ASOs) #Biotechnology #Rare disease #SynaptixBio

Biotech selects ASO drug candidate for incurable rare disease

Oxford-based SynaptixBio, which is developing a therapy for a rare, deadly, and currently incurable rare disease (H-ABC), says it has identified the drug it will take forward into clinical trials.  The drug, SB H-19642, is an antisense oligonucleotide (ASO), which is a short strand of synthetic DNA… Read More

#News

#Antisense Oligonucleotides (ASOs) #Collaboration #Evotec #Partnership #Rare disease #SynaptixBio

SynaptixBio and Evotec extend rare disease therapies partnership

SynaptixBio and Evotec have announced they are extending their partnership to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy. The drug research was originally carried out by the Children’s Hospital of Philadelphia (CHOP), the world’s leading centre for leukodystrophy research,… Read More

#News

Demyelination of neuron
#Antisense Oligonucleotides (ASOs) #FDA #Orphan drugs #Rare disease #SynaptixBio

FDA Orphan Drug Designation awarded to rare disease therapies

UK-based biotech SynaptixBio has secured a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). The company received its first ODD in early 2023 for a therapeutic that targets Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC), the most severe… Read More

#News #Regulatory

Medical researcher
#Funding #Genetics / genomics #Investment #Paediatrics #Rare disease #SynaptixBio

‘Virtual’ biotech targets R&D funding on rare disease therapy

UK biotech firm SynaptixBio has secured £13.2 million to fund its development of the world’s first treatment for TUBB4A-related leukodystrophy, a rare, incurable and deadly disease. The company successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the… Read More

#Business & Investment #News

Demyelination of neuron
#FDA #Muscular dystrophy #Paediatrics #Rare disease #SynaptixBio

Treatment for leukodystrophy could be “revolutionary”

The US Food and Drug Administration (FDA) has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children.  RPDs are designed to encourage the development of new drugs with high unmet… Read More

#Editor's Choice #News #Regulatory